Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Psychosurgery01:30

Psychosurgery

Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Psychiatrische diagnostiek anno 2025].

Tijdschrift voor psychiatrie·2025
Same author

[The history of psychiatric diagnostic concepts].

Tijdschrift voor psychiatrie·2025
Same author

Aspirin delays preterm birth in pregnancies at high risk for preterm pre-eclampsia: evidence from randomized clinical trial in Asia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

One decade of point-prevalence surveys for carriage of extended-spectrum beta-lactamase-producing enterobacterales: whole genome sequencing based prevalence and genetic characterization in a large Dutch teaching hospital from 2013 to 2022.

Antimicrobial resistance and infection control·2024
Same author

Improving selection procedures in health professions education from the applicant perspective: an interview study.

BMC medical education·2024
Same author

Impact of performance and information feedback on medical interns' confidence-accuracy calibration.

Advances in health sciences education : theory and practice·2023

Related Experiment Video

Updated: Jul 6, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

[Beta-blockers and electroconvulsive therapy: a review].

W W van den Broek1, T H N Groenland, P G H Mulder

  • 1afdeling Psychiatrie, Erasmus mc, Postbus 2040, 3000 CA Rotterdam. w.w.vandenbroek@erasmusmc.nl.

Tijdschrift Voor Psychiatrie
|April 10, 2008
PubMed
Summary

Beta-blockers like esmolol can manage cardiovascular issues during electroconvulsive therapy (ECT). Esmolol may shorten seizure duration, with effects depending on dosage, and is recommended for patients with cardiovascular risks.

More Related Videos

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

Related Experiment Videos

Last Updated: Jul 6, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

Area of Science:

  • Cardiovascular Pharmacology
  • Neuroscience
  • Anesthesiology

Context:

  • Patients with cardiovascular disorders undergoing electroconvulsive therapy (ECT) often require management for tachycardia and hypertension.
  • The use of beta-adrenergic blocking agents during ECT is a critical consideration for patient safety and treatment efficacy.

Purpose:

  • To review the effects of beta-blockers on seizure duration and cardiovascular parameters in patients undergoing ECT.
  • To identify optimal beta-blocker choices for ECT administration in patients with and without cardiovascular risk factors.

Summary:

  • A systematic search identified randomized placebo-controlled trials investigating beta-blockers in ECT.
  • Esmolol was frequently used, showing potential to shorten seizure duration in a dose-dependent manner.
  • Bilateral electrode placement and pre-seizure esmolol administration are advised for at-risk patients.

Impact:

  • Esmolol is identified as a preferred beta-blocker for ECT, particularly for managing cardiovascular responses.
  • Labetalol presents an alternative, though its longer half-life is a drawback.
  • Landiolol shows promise as a future alternative due to its favorable pharmacokinetic and pharmacodynamic profile.